Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03480360 · ClinicalTrials.gov registry record · Phase 3
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
A Phase 3 study of Lymphoma and Acute Myeloid Leukemia, sponsored by Dartmouth-Hitchcock Medical Center.
- Active
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03480360: Active Phase 3 study of Lymphoma and Acute Myeloid Leukemia, sponsored by Dartmouth-Hitchcock Medical Center.
NCT03480360 is a Phase 3 study of Lymphoma and Acute Myeloid Leukemia that is active but no longer recruiting, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 21 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03480360, a Phase 3 study of Lymphoma and Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Dartmouth-Hitchcock Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a related haploidentical stem cell transplant.
Primary Outcome
Define 100-day survival of subjects
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Tacrolimus
- RADIATION Total Body Irradiation
- DRUG cellcept
Study Locations (1)
New Hampshire
- Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2026-10-17 |
| Phase | Phase 3 |
What the registry record for NCT03480360 still lists
NCT03480360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower).
The record links to 9 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03480360 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT03480360 about?
NCT03480360 is a clinical study titled "Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression". The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a related haploidentical stem ce...
What is the current status of trial NCT03480360?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2018-03-28. Estimated completion is 2026-10-17.
What conditions does trial NCT03480360 study?
This clinical trial studies the following conditions: Lymphoma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Myelofibrosis.
What interventions are being tested in trial NCT03480360?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Tacrolimus (DRUG), Total Body Irradiation (RADIATION), cellcept (DRUG).
Who is sponsoring clinical trial NCT03480360?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03480360 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03480360's enrollment target sits among peer trials
21 244th of 299 higher than 55 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI